Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from CentreWatch

02:25 EST 22nd February 2018 | BioPortfolio

Here are the most relevant search results for "CentreWatch" found in our extensive news archives from over 250 global news sources.

More Information about CentreWatch on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CentreWatch for you to read. Along with our medical data and news we also list CentreWatch Clinical Trials, which are updated daily. BioPortfolio also has a large database of CentreWatch Companies for you to search.

Showing News Articles 1–25 of 552 from CentreWatch

Monday 18th December 2017

Good Pharma Scorecard results show continued drive for transparency

Some of the world’s largest pharmaceu­tical companies have improved the transparency of their clinical trial data disclosures, according to new analysis from Bioethics International, yet many studies for approved drugs still go unreported. Bioethics International’s second Good Phar­ma Scorecard, published in the online medical journal BMJ Open, found that companies have made “meaningful pr...

Dismantling silos key to improving the clinical trial continuum

The focus on technology as a driver of performance improvement in clinical trials is intense, but despite years of valiant efforts, study execution remains far from optimal. For study startup, the data are dismal: Contract cycle times have doubled from an industry median of 1.5 months in 2009–2011 to more than three months in 2014–2015.1 […] The post Dismantling silos key to improving th...

Friday 15th December 2017

Egalet receives FDA tentative approval for expanded label for ARYMO ER

Egalet, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that the FDA has granted tentative approval for an expanded label for ARYMO ER (morphine sulfate) extended-release (ER) tablets C-II for the management of pain severe enough to require daily, around-the-clock, long-term ...

Evotec, CRTD partner to discover novel therapies for retinal diseases

Evotec has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden (CRTD) to discover novel small molecule candidates for retinal diseases. CRTD is a recognized leader in understanding the biology of stem cells to develop new therapies for neurodegenerative and hematological diseases. Under the terms of the collaboration, Evotec will leverage […] The post ...

CTI Clinical Trial and Consulting Services acquires Eurotrials

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Eurotrials, a full-service CRO, with more than 20 years of experience, and strong local expertise in Europe and Latin America. The acquisition strengthens CTI’s existing Real World Evidence business, adding significant presence and expertise in Euro...

Tuesday 12th December 2017

PAREXEL launches Perceptive Cloud

PAREXEL International, a global biopharmaceutical services organization, introduced the Perceptive Cloud to the life sciences industry, as part of the organization’s recent alliance with Microsoft Corp.   Perceptive Cloud elevates PAREXEL Informatics solutions into an enhanced cloud infrastructure built on Microsoft Azure, combining PAREXEL’s extensive industry expertise and innovative techn...

CluePoints hires Borders and Estrella

CluePoints, a provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has announced two new strategic appointments to strengthen its business development team. Nick Borders and Rob Estrella join the CluePoints U.S. team to support its impressive global business growth, allowing the company to increase its expanding client base across North […] The po...

Monday 11th December 2017

First large-scale clinical trials in psilocybin therapy for treatment-resistant depression launches

COMPASS Pathways, a healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it is partnering with Worldwide Clinical Trials to conduct a major program of late-stage clinical trials for psilocybin therapy for treatment-resistant depression. Depression is the leading cause of ill-health and disability worldwide, and one of the faste...

Distributed Bio, Boehringer Ingelheim announce SuperHuman Platform Transfer

Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce an agreement with Boehringer Ingelheim to license the Distributed Bio SuperHuman Platform for accelerating biotherapeutics discovery across therapeutic areas. “The SuperHuman Platform represents the culmination of a decade of our research in computational library de...

Zilliqa and Global Brain Blockchain Labs partner

Zilliqa, a highly anticipated blockchain platform based on the technology of sharding, has announced a partnership with GB Blockchain Labs (GBBL), the blockchain arm of Global Brain, one of the largest VC firms in Japan. Zilliqa will also be part of the Global Brain Alliance Forum 2017 to be held in Tokyo on December 8. “We […] The post Zilliqa and Global Brain Blockchain Labs partner app...

Illinois Biotechnology Innovation Organization adds Astellas’ Walt Johnston as chairman

Astellas’ Walt Johnston has been elected as chairman of the Illinois Biotechnology Innovation Organization (iBIO) and iBIO Institute Boards of Directors. He succeeds Timothy P Walbert, Horizon Pharma, who served as chairman for the past two years and who will continue to serve on the Board and Executive Committee as Immediate Past Chairman. iBIO, founded […] The post Illinois Biotechnology...

Good Pharma Scorecard judges clinical trial transparency

Bioethics International announced the second publication of its Good Pharma Scorecard (GPS), an annual index ranking large pharmaceutical companies and new drugs on their clinical trial transparency, in BMJ Open. Bioethics International is a not-for-profit organization dedicated to raising the bar on ethics, trustworthiness, and patient-centricity in pharma. Two of eleven ranked companies—Johns...

NIH’s All of Us Research Program, NLM collaborate on outreach efforts through libraries

NIH’s All of Us Research Program and the National Library of Medicine (NLM) have teamed up in a landmark effort to advance precision medicine for the benefit of communities through local libraries. Traditional healthcare takes a “one-size fits all” approach, but precision medicine is healthcare that is “tailored to a person based on things unique […] The post NIH’s All of Us Resear...

Health disparities and clinical trial patient recruitment

Despite remarkable improvements in the number of people with healthcare coverage and the vast improvements in many healthcare technologies, not everyone in the nation has benefited equally. Individuals who are low-income, a racial/ethnic minority or who are disadvantaged or disabled typically do not get involved in cutting-edge medical research.  Clinical trial participation is one way […] ...

Friday 8th December 2017

Bioclinica launches Clinical Adjudication for enhanced trials safety and efficacy

Bioclinica, a provider of technology-enabled solutions for clinical research, launched Bioclinica Clinical Adjudication, a transformational offering in which medical specialists and researchers, backed by advanced technology, lead independent Clinical Event Committee (CEC) review. The new service enables the independent adjudication of clinical events in conformance with regulatory requirements go...

FDA announces approval of first breakthrough-designated test

The FDA approved the FoundationOne CDx (F1CDx), the first breakthrough-designated, next generation sequencing (NGS)-based in vitro diagnostic (IVD) test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. The Centers for Medicare & Medicaid Services (CMS) at the same time proposed coverage of the F1CDx. The test […] The post FDA announces ap...

FDA approves first biosimilar for certain breast and stomach cancers

The FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second […] The post FD...

Johnson & Johnson and partners launch Mosaic HIV-1 Preventive Vaccine

Johnson & Johnson announced that its Janssen Pharmaceutical Companies, together with a consortium of global partners, have initiated the first efficacy study for an investigational mosaic HIV-1 preventive vaccine. The Bill & Melinda Gates Foundation and National Institutes of Health are joining forces with Johnson & Johnson to advance the potential prevention option, which is […]...

Certara introduces new investigator awards program in Australia

Certara, a global provider in model-informed drug development and regulatory science, announced that Leigh Farrell, Ph.D., Vice President of Corporate Strategy and Business Development, is presenting the inaugural Certara New Investigator Awards in association with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). The presentation will take place tod...

Tuesday 5th December 2017

Ra touts positive interim results from paroxysmal nocturnal hemoglobinuria study

Ra Pharmaceuticals announced positive interim results from the company’s ongoing, global phase II clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as ...

Monday 4th December 2017

Report: Improvements needed for sub-optimal clinical trial design in pancreatic cancer

Progress in pancreatic adenocarcinoma trials is sluggish, which is often attributed to low clinical trial recruitment and substandard design. This results in an inadequate understanding of this notoriously difficult-to-treat disease and poor outcomes for patients, according to GlobalData, a leading data and analytics company. Clinical trial accrual is poor in pancreatic cancer and there is […...

Applied BioMath, Syntimmune collaborate onautoimmune diseases

Applied BioMath, a provider in applying mechanistic modeling to drug research and development, announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune’s ongoing clinical trials. Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune’s lead drug candidate...

Melinta Therapeutics to acquire Infectious Disease Business from The Medicines Company

Melinta Therapeutics, a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that Melinta and The Medicines Company have entered into an agreement pursuant to which Melinta will acquire the infectious disease business from The Medicines Company. This includes three marketed products: recently approved and launched Vabomere (vab...

Blue Oak and PsychoGenics partner on drug discovery

Blue Oak Pharmaceuticals and PGI Drug Discovery have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions. Under the terms of the agreement, PsychoGenics is providing access to its powerful phenotypic discovery platforms, including its SmartCube system and machine learning expertise, for unbiased discovery of novel therapeutics for br...

NIH’s All of Us Research Program, National Library of Medicine partner

NIH’s All of Us Research Program and the National Library of Medicine (NLM) have teamed up to raise awareness about the program, a landmark effort to advance precision medicine. Through this collaboration, the National Network of Libraries of Medicine has received a $4.5 million award to support community engagement efforts by public libraries across the United States […] The post NIH’...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks